# FiscalNote Holdings, Inc.: financial statements, quarterly

NOTE · OTC · CIK 1823466 · [Industrials](/sectors/industrials.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/note.md) · [Financials](/companies/note/financials.md) · [Filings](/companies/note/filings.md) · [Insiders](/companies/note/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/note/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [34.0](/filings/0000950170-24-125486.md) | [34.3 d](/filings/0000950170-25-048724.md) | [32.1](/filings/0000950170-25-070383.md) | [29.2](/filings/0000950170-25-109434.md) | [29.4](/filings/0001193125-25-274550.md) | [29.5 d](/filings/0001193125-26-120769.md) | [27.5](/filings/0001193125-26-217061.md) | [23.3](/filings/0001193125-26-342638.md) | [22.4](/filings/0001193125-25-274550.md) | [22.2 d](/filings/0001193125-26-120769.md) | [20.0](/filings/0001193125-26-217061.md) | [19.6](/filings/0001193125-26-342638.md) |
| Research and development | $m | [4.5](/filings/0000950170-24-125486.md) | [4.0 d](/filings/0000950170-25-048724.md) | [3.5](/filings/0000950170-25-070383.md) | [3.2](/filings/0000950170-25-109434.md) | [3.3](/filings/0001193125-25-274550.md) | [2.9 d](/filings/0001193125-26-120769.md) | [3.1](/filings/0001193125-26-217061.md) | [2.3](/filings/0001193125-26-342638.md) | [2.1](/filings/0001193125-25-274550.md) | [2.1 d](/filings/0001193125-26-120769.md) | [2.0](/filings/0001193125-26-217061.md) | [1.6](/filings/0001193125-26-342638.md) |
| Operating income | $m | [(13.5)](/filings/0000950170-24-125486.md) | [(39.9) d](/filings/0000950170-25-048724.md) | [(11.4)](/filings/0000950170-25-070383.md) | [(8.0)](/filings/0000950170-25-109434.md) | [(6.8)](/filings/0001193125-25-274550.md) | [(5.7) d](/filings/0001193125-26-120769.md) | [(13.8)](/filings/0001193125-26-217061.md) | [(7.4)](/filings/0001193125-26-342638.md) | [(9.7)](/filings/0001193125-25-274550.md) | [(18.6) d](/filings/0001193125-26-120769.md) | [(42.5)](/filings/0001193125-26-217061.md) | [(24.1)](/filings/0001193125-26-342638.md) |
| Income tax | $m | [(0.1)](/filings/0000950170-24-125486.md) | [0.0 d](/filings/0000950170-25-048724.md) | [1.4](/filings/0000950170-25-070383.md) | [0.3](/filings/0000950170-25-109434.md) | [(0.6)](/filings/0001193125-25-274550.md) | [(0.6) d](/filings/0001193125-26-120769.md) | [(0.0)](/filings/0001193125-26-217061.md) | [(0.8)](/filings/0001193125-26-342638.md) | [(0.2)](/filings/0001193125-25-274550.md) | [(0.2) d](/filings/0001193125-26-120769.md) | [(0.2)](/filings/0001193125-26-217061.md) | [(0.1)](/filings/0001193125-26-342638.md) |
| Net income | $m | [(14.5)](/filings/0000950170-24-125486.md) | [(50.7) d](/filings/0000950170-25-048724.md) | [50.6](/filings/0001193125-25-274550.md) | [(12.8)](/filings/0001193125-25-274550.md) | [(14.9)](/filings/0001193125-25-274550.md) | [(13.4) d](/filings/0001193125-26-120769.md) | [(4.3)](/filings/0001193125-26-342638.md) | [(13.3)](/filings/0001193125-26-342638.md) | [(24.9)](/filings/0001193125-25-274550.md) | [(22.9) d](/filings/0001193125-26-120769.md) | [(43.6)](/filings/0001193125-26-342638.md) | [(27.8)](/filings/0001193125-26-342638.md) |
| Diluted EPS | $ per share | [(0.11)](/filings/0000950170-24-125486.md) | not reported | [0.37](/filings/0000950170-25-070383.md) | [(0.09)](/filings/0000950170-25-109434.md) | [(1.33)](/filings/0001193125-25-274550.md) | not reported | [(0.34)](/filings/0001193125-26-217061.md) | [(1.00)](/filings/0001193125-26-342638.md) | [(1.73)](/filings/0001193125-25-274550.md) | not reported | [(2.39)](/filings/0001193125-26-217061.md) | [(1.06)](/filings/0001193125-26-342638.md) |
| Basic EPS | $ per share | [(0.11)](/filings/0000950170-24-125486.md) | not reported | [0.39](/filings/0000950170-25-070383.md) | [(0.09)](/filings/0000950170-25-109434.md) | [(1.33)](/filings/0001193125-25-274550.md) | not reported | [(0.34)](/filings/0001193125-26-217061.md) | [(1.00)](/filings/0001193125-26-342638.md) | [(1.73)](/filings/0001193125-25-274550.md) | not reported | [(2.39)](/filings/0001193125-26-217061.md) | [(1.06)](/filings/0001193125-26-342638.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [16.5](/filings/0000950170-23-063323.md) | [16.5](/filings/0000950170-25-048724.md) | [36.5](/filings/0000950170-24-057861.md) | [30.6](/filings/0000950170-24-094185.md) | [25.7](/filings/0000950170-24-125486.md) | [28.8](/filings/0001193125-26-120769.md) | [41.7](/filings/0000950170-25-070383.md) | [34.0](/filings/0000950170-25-109434.md) | [26.7](/filings/0001193125-25-274550.md) | [24.3](/filings/0001193125-26-342638.md) | [23.8](/filings/0001193125-26-217061.md) | [18.0](/filings/0001193125-26-342638.md) |
| Current assets | $m | [48.2](/filings/0000950170-23-063323.md) | [49.8](/filings/0000950170-25-048724.md) | [69.7](/filings/0000950170-24-057861.md) | [62.0](/filings/0000950170-24-094185.md) | [54.4](/filings/0000950170-24-125486.md) | [57.2](/filings/0001193125-26-120769.md) | [65.5](/filings/0000950170-25-070383.md) | [56.7](/filings/0000950170-25-109434.md) | [49.1](/filings/0001193125-25-274550.md) | [45.6](/filings/0001193125-26-342638.md) | [43.1](/filings/0001193125-26-217061.md) | [33.9](/filings/0001193125-26-342638.md) |
| Total assets | $m | [401](/filings/0000950170-23-063323.md) | [371](/filings/0000950170-25-048724.md) | [358](/filings/0000950170-24-057861.md) | [346](/filings/0000950170-24-094185.md) | [338](/filings/0000950170-24-125486.md) | [326](/filings/0001193125-26-120769.md) | [300](/filings/0000950170-25-070383.md) | [288](/filings/0000950170-25-109434.md) | [274](/filings/0001193125-25-274550.md) | [255](/filings/0001193125-26-342638.md) | [213](/filings/0001193125-26-217061.md) | [182](/filings/0001193125-26-342638.md) |
| Current liabilities | $m | [65.1](/filings/0000950170-23-063323.md) | [65.7](/filings/0000950170-25-048724.md) | [63.8](/filings/0000950170-24-057861.md) | [61.4](/filings/0000950170-24-094185.md) | [66.8](/filings/0000950170-24-125486.md) | [51.3](/filings/0001193125-26-120769.md) | [51.0](/filings/0000950170-25-070383.md) | [45.4](/filings/0000950170-25-109434.md) | [48.5](/filings/0001193125-25-274550.md) | [44.4](/filings/0001193125-26-342638.md) | [156](/filings/0001193125-26-217061.md) | [148](/filings/0001193125-26-342638.md) |
| Total liabilities | $m | [317](/filings/0000950170-23-063323.md) | [327](/filings/0000950170-25-048724.md) | [252](/filings/0000950170-24-057861.md) | [239](/filings/0000950170-24-094185.md) | [239](/filings/0000950170-24-125486.md) | [228](/filings/0001193125-26-120769.md) | [198](/filings/0000950170-25-070383.md) | [191](/filings/0000950170-25-109434.md) | [198](/filings/0001193125-25-274550.md) | [193](/filings/0001193125-26-342638.md) | [189](/filings/0001193125-26-217061.md) | [182](/filings/0001193125-26-342638.md) |
| Long-term debt | $m | [213](/filings/0000950170-23-063323.md) | [222](/filings/0000950170-25-048724.md) | [153](/filings/0000950170-24-057861.md) | [146](/filings/0000950170-24-094185.md) | [142](/filings/0000950170-24-125486.md) | [147](/filings/0001193125-26-120769.md) | [118](/filings/0000950170-25-070383.md) | [117](/filings/0000950170-25-109434.md) | [125](/filings/0001193125-25-274550.md) | [126](/filings/0001193125-26-342638.md) | [11.5](/filings/0001193125-26-217061.md) | [12.4](/filings/0001193125-26-342638.md) |
| Current portion of debt | $m | [0.1](/filings/0000950170-23-063323.md) | [0.1](/filings/0000950170-25-048724.md) | [0.1](/filings/0000950170-24-057861.md) | [0.1](/filings/0000950170-24-094185.md) | [10.0](/filings/0000950170-24-125486.md) | [0.0](/filings/0001193125-26-120769.md) | [0.0](/filings/0000950170-25-070383.md) | [0.0](/filings/0000950170-25-109434.md) | [6.3](/filings/0001193125-25-274550.md) | [2.8](/filings/0001193125-26-342638.md) | [112](/filings/0001193125-26-217061.md) | [107](/filings/0001193125-26-342638.md) |
| Shareholders' equity | $m | [83.6](/filings/0000950170-24-125486.md) | [43.5](/filings/0001193125-26-120769.md) | [106](/filings/0001193125-25-274550.md) | [107](/filings/0001193125-25-274550.md) | [98.5](/filings/0001193125-25-274550.md) | [97.8](/filings/0001193125-26-342638.md) | [98.7](/filings/0001193125-26-342638.md) | [95.1](/filings/0001193125-26-342638.md) | [75.5](/filings/0001193125-25-274550.md) | [62.0](/filings/0001193125-26-342638.md) | [24.8](/filings/0001193125-26-342638.md) | [0.3](/filings/0001193125-26-342638.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Current portion of debt: us-gaap:LongTermDebtCurrent
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(11.7) d](/filings/0000950170-24-125486.md) | [(3.6) d](/filings/0000950170-25-048724.md) | [2.7](/filings/0000950170-25-070383.md) | [(3.7) d](/filings/0000950170-25-109434.md) | [(3.0) d](/filings/0001193125-25-274550.md) | [(1.3) d](/filings/0001193125-26-120769.md) | [3.3](/filings/0001193125-26-217061.md) | [(6.2) d](/filings/0001193125-26-342638.md) | [(8.3) d](/filings/0001193125-25-274550.md) | [(0.3) d](/filings/0001193125-26-120769.md) | [3.0](/filings/0001193125-26-217061.md) | [(2.1) d](/filings/0001193125-26-342638.md) |
| Capital expenditure | $m | [1.9 d](/filings/0000950170-24-125486.md) | [2.0 d](/filings/0000950170-25-048724.md) | [1.7](/filings/0000950170-25-070383.md) | [2.7 d](/filings/0000950170-25-109434.md) | [2.4 d](/filings/0001193125-25-274550.md) | [2.0 d](/filings/0001193125-26-120769.md) | [2.0](/filings/0001193125-26-217061.md) | [1.5 d](/filings/0001193125-26-342638.md) | [2.1 d](/filings/0001193125-25-274550.md) | [1.6 d](/filings/0001193125-26-120769.md) | [1.7](/filings/0001193125-26-217061.md) | [1.7 d](/filings/0001193125-26-342638.md) |
| Share repurchases | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquireProductiveAssets
- Share repurchases: not reported

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [96.2](/filings/0000950170-23-063323.md) | [133](/filings/0000950170-24-057861.md) | [134](/filings/0000950170-24-094185.md) | [129](/filings/0000950170-24-125486.md) | [146](/filings/0000950170-25-070383.md) | [134](/filings/0000950170-25-109434.md) | [11.3](/filings/0001193125-25-274550.md) | [12.6](/filings/0001193125-26-217061.md) | [13.3](/filings/0001193125-26-342638.md) | [14.4](/filings/0001193125-25-274550.md) | [18.2](/filings/0001193125-26-217061.md) | [26.1](/filings/0001193125-26-342638.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 121,449,403 at 2022-08-02, from the cover of the [10-Q filed 2022-08-22](/filings/0001104659-22-093355.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:48 ET. No prices; not investment advice.